A2Z Cust2Mate Solutions Corp (AZ) Stock News

Dimensional Fund Advisors Ltd. has disclosed a 1.67% interest in Beazley PLC, comprising 10,019,549 ordinary shares as of June 15, 2026. The disclosure includes a sale of 98,459 shares at 12.83 GBP per unit and a transfer in of 4,826 shares. Dimensional expressly disclaims beneficial ownership and notes it lacks discretion over 162,517 of the shares disclosed.

K-Tech Solutions Company Limited and Aurora AZ Energy Ltd. announced that construction has begun on an initial 5 MW capacity phase of their joint venture to develop computing infrastructure in Alberta, Canada. The project includes onsite technical testing to validate the integration of Aurora's natural gas power infrastructure with K-Tech's high-density computing systems, serving as a proof-of-concept for a planned 100 MW flagship deployment.

Harrow announced the re-launch of VERKAZIA, a prescription therapy for vernal keratoconjunctivitis (VKC), a chronic allergic eye disease primarily affecting children. The company is implementing a comprehensive commercial strategy focused on physician education, patient access, and affordability. VERKAZIA is a calcineurin inhibitor that addresses underlying inflammatory mechanisms and reduces the need for steroid rescue therapy, which carries risks like glaucoma and cataract formation.

Daz 3D announced the release of Daz Studio 6, featuring Victoria AI Chat integrated directly into the application, faster asset loading, improved content organization, and support for the latest NVIDIA GPUs. The update focuses on reducing workflow interruptions for 3D artists through enhanced tools for managing large content libraries, viewport performance improvements, and new rendering capabilities.

Dimensional Fund Advisors Ltd. has disclosed a 2.05% interest in Beazley PLC, comprising 12,315,078 ordinary shares as of May 28, 2026. The disclosure includes a sale of 44,449 shares at 12.81 GBP per unit and a transfer in of 2,245 shares. Dimensional expressly disclaims beneficial ownership and notes it lacks discretion over 229,417 of the shares disclosed.

Azenta, Inc. (AZTA) faces an ongoing securities fraud investigation following disappointing Q2 2026 earnings results on May 5, 2026. The company missed consensus estimates, reported a $149 million goodwill impairment, and significantly reduced its 2026 guidance, causing the stock to plummet 25.3% to $18.38 per share. A securities law firm is investigating potential federal securities law violations and urging affected shareholders to contact them.

MedX Holdings announced Q1 2026 results with continued net profitability and debt reduction. The company is rebranding to Dazed Inc. (ticker: DAZE) and expanding with three new LazyDaze + Coffeeshop locations in San Marcos, Houston, and Baltimore. The company is also finalizing partnerships for Lazydaze Coffee and K-Cup products and capitalizing on cannabis's federal reclassification to Schedule III.

Austin, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- MEDX HOLDINGS ANNOUNCES Q1 2026 HIGHLIGHTS, MULTI-CITY EXPANSION, AND CORPORATE ACTION TO REBRAND AS DAZED INC. (TICKER: DAZE) AUSTIN, Texas — May 22, 2026 — MedX Holdings, Inc. (OTC: MEDH ), a leader in the converging cannabis, hemp, and hospitality sectors, today announced its operational and financial highlights for the first quarter of 2026. Building on the net profitability achieved in Q4 2025, the company continues to execute its aggressive expansion strategy, marked by upcoming store openings, strategic product partnerships, and a major corporate rebranding initiative to align with its rapidly growing consumer footprint. Corporate Action: Rebranding to Dazed Inc. To align the company's corporate identity with its flagship consumer brands and long-term vision, MedX Holdings has announced its intention and initiated the required corporate actions to change its name to Dazed Inc. Alongside this name change, the company intends to request a formal ticker symbol change to DAZE . This strategic evolution reflects the company's dominant focus on scaling the Lazydaze franchise ecosystem and Dazed Distribution networks. Q1 Financial and Operational Milestone Highlights Continued Debt Reduction: MedX sustained its disciplined focus on balance sheet strength, further paring down long-term liabilities throughout Q1 to enhance cash flow and shareholder equity. Lazydaze Coffee & K-Cup Partnerships: The company is currently in the final stages of talks with potential strategic partners to massively scale ... Full story available on Benzinga.com

Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026, but disclosed a $149 million goodwill impairment tied to its Multiomics segment in May 2026, alongside a $160.8 million net loss and substantial guidance reduction. The company did not reference the impairment risk during its February reaffirmation, prompting an investigation into potential securities law violations.

Law firm Bragar Eagel & Squire is investigating Azenta, Inc. following the company's May 5, 2026 announcement of disappointing Q2 fiscal 2026 results, execution gaps, and a $149 million goodwill impairment charge. Azenta significantly lowered its full-year guidance and extended its long-range plan targets, causing its stock to plummet 25% from $24.61 to $18.38 per share.

Azenta, Inc. reported disappointing Q2 fiscal 2026 results with execution gaps and weak demand, recording a $149 million goodwill impairment charge. The company significantly reduced its full-year guidance and extended long-range plan targets, causing its stock to plunge 25% on May 6, 2026. Law firm Kirby McInerney LLP is investigating potential securities law violations by the company and its senior management.

The Schall Law Firm announced an investigation into Azenta, Inc. for potential securities law violations following the company's May 5, 2026 earnings announcement. Azenta missed analyst estimates on revenue and EPS due to execution shortfalls and weak demand, leading to a 25.3% stock price decline and a reduced full-year 2026 outlook.

English Conference Call Scheduled at 10am Eastern Time and 5pm Israel Time CAESAREA, Israel , May 18, 2026 /PRNewswire/ -- Turpaz Industries Ltd. (TASE: TRPZ), a global company that develops and manufactures thousands of flavor and fragrance extracts, intermediates and specialty fine ingredients and markets and sells them in more than 95 countries around the world, today announced its financial results for the first quarter ended March 31, 2026, demonstrating continued double-digit growth across all key financial metrics and a significant acceleration in its global expansion. Q1 2026 Financial Highlights Revenues grew 38.6% to a record $83.6 million, with organic growth of approximately 9%; Adjusted EBITDA increased 42.4% to $19.4 million, representing 23.2% of revenues; Net income more than doubled, growing 104.5% to $11.1 million; Non-GAAP net income grew by 48.8% to $11.7 million. Current revenue run-rate (as of reporting date) of approximately $380 million following the recent acquisitions in the U.S. and France. Management Comment Karen Cohen Khazon, Chief Executive Officer of Turpaz Industries, said, "We started 2026 with continued strong growth and record results, reflecting the strength of Turpaz's growth strategy and our execution capabilities. The combination of strong organic growth together with synergistic acquisitions continues to prove itself as a significant growth engine." "The recent acquisitions we completed in the U.S. and France represent an important strategic step in expanding our global footprint, strengthening our presence in key markets and segments with high growth potential, primarily fine fragrances and North America." "The Group's financial strength, together with cooperation with leading global banks and financial institutions, combined with the extensive experience of Turpaz's management team and its dedicated employees, enables us to c

Azenta, Inc. (NASDAQ: AZTA) recorded a $149 million goodwill impairment and slashed FY 2026 guidance on May 5, 2026, just weeks after reaffirming confidence in its growth trajectory on the Q1 earnings call. The impairment was tied to the Multiomics segment. Levi & Korsinsky is investigating whether the company made materially misleading statements to investors regarding risks to the Multiomics segment and factors underlying the goodwill impairment.

Azenta, Inc. reported disappointing Q2 fiscal 2026 results with execution gaps and weak demand, recording a $149 million goodwill impairment charge. The company significantly reduced its full-year guidance and extended long-range plan targets, causing its stock to plunge 25% from $24.61 to $18.38. Law firm Kirby McInerney LLP is investigating potential securities law violations by the company and its senior management.

A securities fraud investigation has been announced against Azenta, Inc. after the company missed Q2 2026 earnings estimates, reported a $149 million goodwill impairment, and significantly reduced its 2026 guidance. The stock fell 25.3% to $18.38 on May 6, 2026, prompting a law firm to seek investors who suffered losses.

Law firm Bragar Eagel & Squire is investigating Azenta, Inc. following the company's May 5, 2026 announcement of disappointing Q2 fiscal 2026 results, execution gaps, and a $149 million goodwill impairment charge. Azenta significantly lowered its full-year guidance and extended its long-range plan targets, causing its stock to plummet 25% from $24.61 to $18.38 per share.

Collegium Pharmaceutical completed its acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for approximately $650 million. The acquisition is expected to be immediately accretive and includes patent protection through 2037. Collegium raised its 2026 financial guidance, projecting total product revenues of $865-$895 million and adjusted EBITDA of $475-$500 million, with expected annual synergies exceeding $50 million.